Hirohito Shimizu

Results-driven and innovative professional with ~10 years of experience in Medical Affairs across Japan and the APAC region. Spearheaded transformational initiatives in a 150+ member organization, enhancing organizational execution and competitiveness while advancing patient-centered outcomes. Recognized for fostering cross-functional collaboration and delivering high-impact regional programs, including ME.ai, ANGen, and ONE Voice 4 Impact, which earned accolades for advancing Medical Excellence. Proven ability to lead teams, develop talent, and drive strategic alignment, making a significant impact in both domestic and global operations.

• Japanese: Native proficiency
• English: Professional working proficiency

• Field Medical Excellence Performance Metrics Lead, APAC (Jul 2024 - Mar 2025): Developed regional metrics and partnered with Business Insights to optimize visualization, advancing APAC Medical Affairs excellence through initiatives like ANGen and supporting change management for local markets.

• Regional Medical Advisor for JNJ1900, APAC (Mar 2025 - Nov 2025; ongoing): Deliver medical strategy for JNJ1900 in Head & Neck and Lung Cancer by collaborating with APAC and Global Medical Affairs teams, addressing evidence needs for WWMAS and IEGP, optimizing KOL engagement, and supporting clinical trial site readiness across the region.

• WeRecognize!!(Credo Award) – Execution (2024)
• APAC Award – Leading for People (2024)
• MAF IMPACT Award – Patient Impact (2024)
• Bronze MAF Purpose Awards – Strategic Leadership (2024)
• Best IMPACT Award (2024)

Publications

• Miyashiro M, Ishii Y, Miyazaki C, Shimizu H, Masuda J. A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan. Rheumatol Ther. 10(3):615-634. (2023)
• Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: Results from a Japanese post-marketing surveillance study. Mod Rheumatol. 31(3):556-565. (2021)
• Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data. Mod Rheumatol. 31(3):566-574. (2021)
• Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Effectiveness of golimumab dose escalation in Japanese patients with rheumatoid arthritis: post-hoc analysis of post-marketing surveillance data. Rheumatol Ther. 7(2):311-25. (2020)
• Okazaki M, Kobayashi H, Shimizu H, Ishii Y, Yajima T, Kanbori M. Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan. Rheumatol Ther. 5:135-148 (2018).

Oral Presentations

• The 33rd Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research. "Clinical benefits of Golimumab in Japanese patients with active rheumatoid arthritis refractory to treatment with a biologic agent: evidence from real-world data". (2018)